Trial Profile
A phase 1 clinical trial of OLX10020
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2019
Price :
$35
*
At a glance
- Drugs OLX 10020 (Primary)
- Indications Age-related macular degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration
- Focus Adverse reactions
- 05 Feb 2019 New trial record
- 17 Jan 2019 According to an OliX Pharmaceuticals media release, an IND application is planned to be submitted to the FDA to initiate a Phase 1 within this year.